Talphera (TLPH) Stock Price, News & Analysis

Company Overview

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Key Stats

• Today's Range: $0.60 to $0.69
• 50-Day Range: $0.61 to $1.16
• 52-Week Range: $0.60 to $1.61
• Volume: 76,366 shs
• Average Volume: 91,024 shs
• Market Capitalization: $10.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Strong Buy

Talphera Stock Analysis - MarketRank™

Talphera scored higher than 58% of companies evaluated by MarketBeat, and ranked 457th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Talphera has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Talphera has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Talphera are expected to decrease in the coming year, from ($0.64) to ($1.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Talphera is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Talphera is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Talphera has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.25% of the float of Talphera has been sold short.

Short Interest Ratio / Days to Cover

Talphera has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Talphera has recently decreased by 51.05%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Talphera does not currently pay a dividend.

Dividend Growth

Talphera does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.25% of the float of Talphera has been sold short.

Short Interest Ratio / Days to Cover

Talphera has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Talphera has recently decreased by 51.05%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for TLPH on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Talphera to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Talphera insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,850.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 3.20% of the stock of Talphera is held by insiders.

Percentage Held by Institutions

Only 37.67% of the stock of Talphera is held by institutions.

TLPH Stock Analysis - Frequently Asked Questions

How have TLPH shares performed this year?

Talphera's stock was trading at $0.7989 on January 1st, 2024. Since then, TLPH shares have decreased by 20.5% and is now trading at $0.6353.
View the best growth stocks for 2024 here.

Who are Talphera's major shareholders?

Talphera's top institutional shareholders include Rosalind Advisors Inc. (4.47%).
View institutional ownership trends.

How do I buy shares of Talphera?

Shares of TLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Talphera own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Talphera investors own include Clearside Biomedical (CLSD), Terran Orbital (LLAP), Adverum Biotechnologies (ADVM), Aptinyx (APTX), Nikola (NKLA), Exela Technologies (XELA) and Xeris Biopharma (XERS).

Company Calendar

• Today: 12/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TLPH
• Previous Symbol: NASDAQ:TLPH
• CUSIP: N/A
• CIK: 1427925
• Web: talphera.com
• Phone: 650-216-3500
• Fax: 650-216-6500
• Employees: 19
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.50
• High Stock Price Target: $6.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +608.3%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-18,400,000.00
• Net Margins: N/A
• Pretax Margin: -5,567.26%
• Return on Equity: -118.46%
• Return on Assets: -65.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.42
• Quick Ratio: 4.42

Sales & Book Value

• Annual Sales: $281,000.00
• Price / Sales: 38.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.83 per share
• Price / Book: 0.77

Miscellaneous

• Outstanding Shares: 17,029,000
• Free Float: 16,484,000
• Market Cap: $10.82 million
• Optionable: Optionable
• Beta: 0.25